Strategies to manage hepatitis C virus (HCV) disease burden
- PMID: 24713006
- DOI: 10.1111/jvh.12249
Strategies to manage hepatitis C virus (HCV) disease burden
Abstract
The number of hepatitis C virus (HCV) infections is projected to decline while those with advanced liver disease will increase. A modeling approach was used to forecast two treatment scenarios: (i) the impact of increased treatment efficacy while keeping the number of treated patients constant and (ii) increasing efficacy and treatment rate. This analysis suggests that successful diagnosis and treatment of a small proportion of patients can contribute significantly to the reduction of disease burden in the countries studied. The largest reduction in HCV-related morbidity and mortality occurs when increased treatment is combined with higher efficacy therapies, generally in combination with increased diagnosis. With a treatment rate of approximately 10%, this analysis suggests it is possible to achieve elimination of HCV (defined as a >90% decline in total infections by 2030). However, for most countries presented, this will require a 3-5 fold increase in diagnosis and/or treatment. Thus, building the public health and clinical provider capacity for improved diagnosis and treatment will be critical.
Keywords: HCV; diagnosis; disease burden; epidemiology; hepatitis C; incidence; mortality; prevalence; scenarios; treatment.
© 2014 John Wiley & Sons Ltd.
Comment in
-
Response to letter to the editor: Strategies to reduce HCV disease burden and HCV transmission need different models, as what works for end-stage liver disease may not work for HCV prevalence: a comment on the results presented in JVH Special Issue.J Viral Hepat. 2014 Dec;21(12):e169-70. doi: 10.1111/jvh.12339. Epub 2014 Sep 29. J Viral Hepat. 2014. PMID: 25262767 No abstract available.
-
Strategies to reduce HCV disease burden and HCV transmission need different models, as what works for end-stage liver disease may not work for HCV prevalence: a comment on the results presented in JVH Special Issue.J Viral Hepat. 2014 Dec;21(12):e167-8. doi: 10.1111/jvh.12340. Epub 2014 Sep 29. J Viral Hepat. 2014. PMID: 25262826 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical